Abstract Number: 0542 • ACR Convergence 2021
Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis
Background/Purpose: Glycoprotein nonmetastatic melanoma protein B (GPNMB) is widely expressed on stromal cells and immune cells. It is involved in various cell functions such as…Abstract Number: 1643 • ACR Convergence 2021
Increased Incidence of Pediatric SLE and Other Interferon Activated Diseases During COVID-19 Pandemic
Background/Purpose: COVID-19, as a member of the Coronavirus family, has been described to trigger host immune response via type I interferon (IFN) signaling pathways with…Abstract Number: 0557 • ACR Convergence 2021
The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway
Background/Purpose: Extensive work in the Alzheimer’s field has shown BACE1 plays an important role in amyloid beta processing. Additionally, there is evidence showing BACE1 regulating…Abstract Number: 1838 • ACR Convergence 2021
Further Construct Validation of the
Background/Purpose: Evaluation of skin is central in clinical management of systemic sclerosis (SSc). Due to the COVID-19 pandemic remote consultations were widely implemented, which inevitably…Abstract Number: 0697 • ACR Convergence 2021
Detection of Autoantibodies Against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort
Background/Purpose: Autoantibodies targeting a muscle-specific autoantigen, four-and-a-half-LIM-domain 1 (FHL1), have been previously identified in patients with idiopathic inflammatory myopathies (IIM) (1). The aim of this…Abstract Number: 1848 • ACR Convergence 2021
Untangling the Gut: A Phenome-Wide Association Study of Drugs and Diseases with Gastrointestinal Dysfunction in Systemic Sclerosis
Background/Purpose: Gastrointestinal dysfunction (SSc-GI) is a significant burden to patients with systemic sclerosis (SSc), particularly in those with longstanding disease. The management of SSc-GI is…Abstract Number: 0716 • ACR Convergence 2021
Marked Capillary Basement Membrane Reduplication Is the Hallmark Histopathological Feature of Scleromyositis
Background/Purpose: Scleromyositis (SM) is an emerging subset of autoimmune myositis (AIM) in patients with features of systemic sclerosis (SSc). SM patients may present without characteristic…Abstract Number: 1849 • ACR Convergence 2021
False Positive Anti-Topoisomerase I (Scl-70) Antibody Results: A Case Series from a Scleroderma Referral Center
Background/Purpose: Systemic sclerosis (SSc) is a progressive autoimmune disease with high morbidity and mortality, making early diagnosis and management critical. Anti-Topoisomerase I antibody (anti-Topo I,…Abstract Number: 1090 • ACR Convergence 2021
Contribution of Scleroderma/Myositis-Related Antibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 134 Patients from a Single Referral Center
Background/Purpose: Immunoblot assays are increasingly used in clinical practice as part of the diagnostic armamentarium of systemic autoimmune rheumatic diseases (SARDs). Our aim was to…Abstract Number: 1852 • ACR Convergence 2021
Healthcare Utilization and Economic Burden in Systemic Sclerosis
Background/Purpose: Systemic Sclerosis (SSc) is a multi-system autoimmune disease, characterized by vasculopathy, fibrosis of the skin and internal organs, and autoimmunity with distinct antibodies. SSc…Abstract Number: 1367 • ACR Convergence 2021
Associations of Esophageal Dysmotility Patterns with Extra-intestinal Features in Patients with Systemic Sclerosis
Background/Purpose: The gastrointestinal (GI) tract is the most commonly affected internal organ in systemic sclerosis (SSc). SSc GI disease is heterogeneous, with some patients experiencing…Abstract Number: 1854 • ACR Convergence 2021
Disease Characteristics and Social Determinants in African Americans with Systemic Sclerosis: A Single Center Experience
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease categorized on the basis of skin involvement as either limited or diffuse cutaneous SSc, the latter…Abstract Number: 1370 • ACR Convergence 2021
Complement Factor D and Factor H Represent Disease and Severity Biomarkers for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe vascular complication of systemic sclerosis (SSc) and a major cause of mortality. Despite significant advances in the…Abstract Number: 1856 • ACR Convergence 2021
Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) carries a highly variable prognosis and to date there are no stratification tools to predict clinical outcomes. Evidence suggests…Abstract Number: 1371 • ACR Convergence 2021
Symptom Management in Systemic Sclerosis: A Pilot Study of a Web-based Intervention Using Peer-Health Coaches
Background/Purpose: People with systemic sclerosis (SSc) have a high burden of chronic symptoms that have dramatic effects on function and quality of life. Fatigue, along…
- 1
- 2
- 3
- …
- 13
- Next Page »